Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Inclusion Criteria:

* Male or female subject \>= 18 years;
* Histologically or cytologically confirmed HER2-positive breast cancer defined as 3+ determined by validated IHC or positive by in situ hybridization (ISH);
* Early-stage (T1c or 2, N1, M0; T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3, N2, M0; T3N1M0; T1c or 2 or 3, N3a or 3b, M0) breast cancer;
* Adequate organ function assessed within 7 days prior to first trial treatment;
* ECOG score 0 or 1;
* Left ventricular ejection fraction (LVEF) ≥ 55% at baseline;

Exclusion Criteria:

* Stage IV (metastatic) breast cancer;
* Inflammatory breast cancer;
* Previous anti-cancer therapy or radiotherapy for any malignancy;
* Major surgery for any reason within 28 days;
* History of uncontrolled intercurrent illness;
* Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance;